These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23682075)

  • 1. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
    Mohebati A; Milne GL; Zhou XK; Duffield-Lillico AJ; Boyle JO; Knutson A; Bosworth BP; Kingsley PJ; Marnett LJ; Brown PH; Akpa EG; Szabo E; Dannenberg AJ
    Cancer Prev Res (Phila); 2013 Jul; 6(7):646-55. PubMed ID: 23682075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.
    Duffield-Lillico AJ; Boyle JO; Zhou XK; Ghosh A; Butala GS; Subbaramaiah K; Newman RA; Morrow JD; Milne GL; Dannenberg AJ
    Cancer Prev Res (Phila); 2009 Apr; 2(4):322-9. PubMed ID: 19336727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
    Li N; Sood S; Wang S; Fang M; Wang P; Sun Z; Yang CS; Chen X
    Clin Cancer Res; 2005 Mar; 11(5):2089-96. PubMed ID: 15756036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
    Pallio G; Bitto A; Pizzino G; Galfo F; Irrera N; Minutoli L; Arcoraci V; Squadrito G; Macrì A; Squadrito F; Altavilla D
    Eur J Pharmacol; 2016 Oct; 789():152-162. PubMed ID: 27450484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
    Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
    Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
    Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
    J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
    Israel E; Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Shapiro J; Cohn J; Rubin P; Drazen JM
    Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1447-51. PubMed ID: 8256883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of zileuton and montelukast in mouse experimental spinal cord injury.
    Genovese T; Rossi A; Mazzon E; Di Paola R; Muià C; Caminiti R; Bramanti P; Sautebin L; Cuzzocrea S
    Br J Pharmacol; 2008 Feb; 153(3):568-82. PubMed ID: 18059327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a highly sensitive liquid chromatography-mass spectrometry method to quantify plasma leukotriene E
    Löfgren L; Forsberg GB; Davidsson P; Eketjäll S; Whatling C
    Prostaglandins Other Lipid Mediat; 2020 Oct; 150():106463. PubMed ID: 32450304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
    Grissom CK; Richer LD; Elstad MR
    Chest; 2005 Feb; 127(2):565-70. PubMed ID: 15705997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
    Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
    Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta.
    Kwak HJ; Park KM; Choi HE; Lim HJ; Park JH; Park HY
    Cell Signal; 2010 Jan; 22(1):80-7. PubMed ID: 19781629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib inhibits 5-lipoxygenase.
    Maier TJ; Tausch L; Hoernig M; Coste O; Schmidt R; Angioni C; Metzner J; Groesch S; Pergola C; Steinhilber D; Werz O; Geisslinger G
    Biochem Pharmacol; 2008 Oct; 76(7):862-72. PubMed ID: 18692027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
    Kane GC; Tollino M; Pollice M; Kim CJ; Cohn J; Murray JJ; Dworski R; Sheller J; Fish JE; Peters SP
    Prostaglandins; 1995 Jul; 50(1):1-18. PubMed ID: 8588068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
    Dovizio M; Tacconelli S; Ricciotti E; Bruno A; Maier TJ; Anzellotti P; Di Francesco L; Sala P; Signoroni S; Bertario L; Dixon DA; Lawson JA; Steinhilber D; FitzGerald GA; Patrignani P
    J Pharmacol Exp Ther; 2012 Apr; 341(1):242-50. PubMed ID: 22262921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.
    Rossi A; Pergola C; Koeberle A; Hoffmann M; Dehm F; Bramanti P; Cuzzocrea S; Werz O; Sautebin L
    Br J Pharmacol; 2010 Oct; 161(3):555-70. PubMed ID: 20880396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
    Gounaris E; Heiferman MJ; Heiferman JR; Shrivastav M; Vitello D; Blatner NR; Knab LM; Phillips JD; Cheon EC; Grippo PJ; Khazaie K; Munshi HG; Bentrem DJ
    PLoS One; 2015; 10(3):e0121402. PubMed ID: 25747113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
    Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
    Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.
    Kekatpure VD; Boyle JO; Zhou XK; Duffield-Lillico AJ; Gross ND; Lee NY; Subbaramaiah K; Morrow JD; Milne G; Lippman SM; Dannenberg AJ
    Cancer Prev Res (Phila); 2009 Nov; 2(11):957-65. PubMed ID: 19843689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.
    Hackshaw KV; Shi Y; Brandwein SR; Jones K; Westcott JY
    J Rheumatol; 1995 Mar; 22(3):462-8. PubMed ID: 7783062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.